Century Therapeutics, Inc. (IPSC)

Century Therapeutics, Inc. (IPSC) Healthcare & Pipeline Overview

Century Therapeutics, Inc. is a biotechnology firm specializing in the development of allogeneic cell therapies for cancer, with a focus on hematological malignancies and solid tumors. Their lead candidate, CNTY-101, targets CD19 in B-cell lymphomas, placing them in the competitive landscape of oncology therapeutics.

What Is the Investment Thesis for IPSC?

Century Therapeutics operates in the high-growth area of allogeneic cell therapies, targeting significant unmet needs in oncology. The company's lead candidate, CNTY-101, and its broader pipeline represent potential value drivers. A gross margin of 90.9% indicates strong potential profitability if clinical trials are successful and products are commercialized. Key catalysts include the progression of CNTY-101 through clinical trials and the development of its other CAR-iNK and CAR-iT candidates. The company's high beta of 1.67 suggests significant volatility, and the negative profit margin of -8.8% reflects ongoing R&D investments and the absence of revenue-generating products. Success hinges on clinical trial outcomes and regulatory approvals.

Based on FMP financials and quantitative analysis

IPSC Key Highlights

• Market Cap of $207.33M reflects investor valuation of Century Therapeutics' pipeline and technology.
• Gross Margin of 90.9% indicates potential for high profitability upon successful commercialization of therapies.
• Profit Margin of -8.8% highlights the company's current focus on research and development, with no products yet generating revenue.
• Beta of 1.67 suggests higher volatility compared to the overall market, typical for biotechnology companies in the clinical stage.
• No Dividend Yield reflects the company's reinvestment of earnings into research and development activities.

Who Are IPSC's Competitors?

IPSC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IPSC's Key Strengths?

• Innovative iPSC-derived allogeneic cell therapy platform.
• Diverse pipeline of CAR-iNK and CAR-iT cell therapy candidates.
• Potential to address limitations of autologous cell therapies.
• Strong intellectual property position.

What Are IPSC's Weaknesses?

• Early-stage clinical development with significant regulatory hurdles.
• High R&D expenses and negative profit margin.
• Reliance on clinical trial outcomes for value creation.
• Competition from established pharmaceutical companies.

What Could Drive IPSC Stock Higher?

• Clinical trial data releases for CNTY-101 in relapsed, refractory B-cell lymphoma.
• Initiation of clinical trials for CNTY-103 in recurrent glioblastoma.
• Advancement of CAR-iNK and CAR-iT candidates through preclinical and clinical development.
• Potential strategic partnerships and collaborations with pharmaceutical companies.
• Continued innovation in iPSC technology and cell engineering.

What Are the Key Risks for IPSC?

• Financial-distress signal — its Altman Z-Score of -2.02 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-53.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays in the development of CNTY-101 and other candidates.
• Regulatory setbacks or rejection of product candidates by the FDA or other regulatory agencies.
• Competition from other cell therapy companies and established pharmaceutical companies.
• Patent challenges or infringement on Century Therapeutics' intellectual property.
• High R&D expenses and the need for additional funding to support clinical development.

What Are the Growth Opportunities for IPSC?

• CNTY-101 Clinical Development: The continued clinical development and potential approval of CNTY-101 for relapsed, refractory B-cell lymphoma represent a significant growth opportunity. Positive clinical trial data and subsequent regulatory approval could drive substantial revenue growth and market share gains in the lymphoma treatment market. The market for lymphoma treatment is estimated to reach billions of dollars, offering a substantial commercial opportunity for Century Therapeutics.
• Expansion of CAR-iNK and CAR-iT Pipeline: The development and clinical advancement of other CAR-iNK and CAR-iT candidates, such as CNTY-103 for glioblastoma, CNTY-102 for B-cell lymphomas, CNTY-104 for AML, and CNTY-106 for multiple myeloma, provide multiple avenues for growth. Each of these programs targets distinct cancer types with significant unmet medical needs, expanding the company's potential market reach and revenue streams.
• Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with larger pharmaceutical companies or other biotechnology firms could accelerate the development and commercialization of Century Therapeutics' cell therapies. Collaborations can provide access to additional funding, expertise, and resources, enhancing the company's ability to navigate the complex regulatory landscape and bring its products to market more efficiently.
• Advancements in iPSC Technology: Continued advancements in iPSC technology and cell engineering could further enhance the efficacy and safety of Century Therapeutics' allogeneic cell therapies. Improvements in cell targeting, persistence, and immune evasion could lead to more effective treatments and a stronger competitive position in the cell therapy market. Investing in research and development to optimize its iPSC platform is crucial for long-term growth.
• Geographic Expansion: Expanding the company's clinical trial programs and commercial operations to new geographic regions, such as Europe and Asia, could unlock additional growth opportunities. These regions represent significant markets for cancer therapies, and establishing a presence in these areas could drive revenue growth and increase the company's global market share. This expansion requires careful planning and execution to navigate regulatory requirements and market dynamics in each region.

What Opportunities Does IPSC Have?

• Positive clinical trial results for CNTY-101 and other candidates.
• Strategic partnerships and collaborations to accelerate development.
• Expansion into new cancer indications and geographic markets.
• Advancements in iPSC technology and cell engineering.

What Threats Does IPSC Face?

• Clinical trial failures or delays.
• Regulatory setbacks or rejection of product candidates.
• Competition from other cell therapy companies.
• Patent challenges or infringement.

What Are IPSC's Competitive Advantages?

• Proprietary iPSC-derived cell therapy platform.
• Pipeline of allogeneic cell therapy candidates targeting various cancers.
• Expertise in cell engineering and immunotherapy.
• Potential for off-the-shelf availability and scalability of therapies.

What Does IPSC Do?

Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Century Therapeutics, Inc. is a biotechnology company dedicated to creating transformative allogeneic cell therapies for the treatment of both solid tumor and hematological malignancies. The company's core technology revolves around using induced pluripotent stem cells (iPSCs) to develop chimeric antigen receptor (CAR)-iNK and CAR-iT cell therapies. Their lead product candidate, CNTY-101, is an allogeneic, iPSC-derived CAR-iNK cell therapy designed to target CD19, a protein expressed on B-cells, making it a potential treatment for relapsed or refractory B-cell lymphomas. In addition to CNTY-101, Century Therapeutics is advancing a pipeline of other allogeneic cell therapy candidates. CNTY-103 is a CAR-iNK candidate targeting CD133+ EGFR for recurrent glioblastoma, a particularly aggressive form of brain cancer. CNTY-102 is a CAR-iT cell therapy targeting CD19 and CD79b, also for relapsed or refractory B-cell lymphomas and other B-cell malignancies. The company is also developing CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia (AML), and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics aims to overcome the limitations of autologous cell therapies, such as manufacturing complexities and patient-specific variability, by developing off-the-shelf allogeneic therapies that can be readily available to a broader patient population. The company's focus on iPSC-derived cell therapies positions it within the rapidly evolving field of cell and gene therapy, with the potential to address significant unmet needs in cancer treatment.

What Products and Services Does IPSC Offer?

• Develop allogeneic cell therapies for cancer treatment.
• Utilize induced pluripotent stem cells (iPSCs) to create cell therapies.
• Focus on chimeric antigen receptor (CAR)-iNK and CAR-iT cell therapies.
• Target both solid tumor and hematological malignancies.
• Advance a pipeline of product candidates, including CNTY-101, CNTY-103, CNTY-102, CNTY-104, and CNTY-106.
• Aim to overcome limitations of autologous cell therapies through off-the-shelf allogeneic therapies.

How Does IPSC Make Money?

• Develop and out-license or commercialize allogeneic cell therapies for cancer.
• Generate revenue through potential partnerships and collaborations with pharmaceutical companies.
• Focus on research and development to advance its pipeline of product candidates.
• Potentially generate revenue through direct sales of approved therapies.

What Industry Does IPSC Operate In?

Century Therapeutics operates within the rapidly evolving biotechnology industry, specifically in the field of cell and gene therapy. The market for cell therapies is projected to experience substantial growth, driven by advancements in genetic engineering and the increasing prevalence of cancer. The competitive landscape includes established pharmaceutical companies and specialized biotechnology firms developing CAR-T cell therapies and other immunotherapies. Century Therapeutics differentiates itself through its focus on allogeneic iPSC-derived cell therapies, which offer the potential for off-the-shelf availability and scalability compared to autologous approaches.

Who Are IPSC's Key Customers?

• Patients with relapsed or refractory B-cell lymphomas.
• Patients with recurrent glioblastoma.
• Patients with acute myeloid leukemia.
• Patients with multiple myeloma.

ROE -53%Key Financial Metrics

Return on equity for Century Therapeutics, Inc. stands at -53.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -45.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.25 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -50.8%, the inverse of the P/E and a quick read on earnings relative to price.

How Century Therapeutics, Inc. Is Valued

Century Therapeutics, Inc. carries a market capitalization of $207.33M, placing it in the micro-cap category. Relative to its peer group, IPSC's quantitative score of 30/100 is below the peer average of 77/100.

F-Score 1/9Financial Health

Century Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.02 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Century Therapeutics, Inc. revenue of about $4.7M for fiscal 2026, with EPS near $-0.45. The estimate reflects 4 contributing analysts.

IPSC Financials

IPSC Latest News

IPSC Analyst Consensus

IPSC MoonshotScore

What Investors Ask About Century Therapeutics, Inc. (IPSC) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources